OpenPV Signal Explorer
FAERS disproportionality dashboard
Reaction

Lipoma reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,554 reports · 48 co-occurring drugs

As of the last recalculation, Lipoma appears in 2,554 FAERS reports alongside 48 co-occurring drug terms. The strongest observed disproportionality signal is TOLTERODINE TARTRATE (PRR 32.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Tolterodine Tartrate3532.232.3
Amlodipine Besylate And Valsartan1511.111.1
Mometasone2410.810.8
Cefuroxime1410.010.0
Irbesartan488.98.9
Meloxicam618.78.8
Captopril108.58.5
Methylprednisolone Acetate88.28.2
Rosuvastatin Calcium277.97.9
Diclofenac Sodium 1%347.87.9
Diclofenac Sodium Topical347.87.9
Diclofenac Sodium Topical Gel, 1%347.87.8
Octreotide Acetate297.87.8
Salmeterol Xinafoate87.67.6
Gemfibrozil147.67.6
Raloxifene Hydrochloride137.37.3
Dolutegravir Sodium87.27.3
Amlodipine Besylate And Benazepril Hydrochloride87.17.1
Fexofenadine Hcl87.17.1
Doxepin Hydrochloride106.56.5
Thyroid, Porcine86.16.1
Lovastatin185.75.8
Infliximab-Dyyb205.65.6
Omalizumab575.65.6
Etonogestrel And Ethinyl Estradiol155.55.5
Bicalutamide105.45.4
Baclofen555.35.3
Risankizumab-Rzaa525.35.3
Adalimumab3955.25.2
Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hcl315.15.1
Sitagliptin404.64.6
Lanreotide Acetate44.24.2
Avapritinib64.04.0
Iohexol43.93.9
Inclisiran33.13.1
Secukinumab593.03.0
Tolvaptan52.82.8
Interferon Beta-1A652.82.8
Alirocumab82.62.6
Isotretinoin152.52.5
Exenatide152.32.3
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate52.32.3
Ranibizumab72.22.2
Diroximel Fumarate32.12.1
Somatropin182.02.0
Emicizumab32.02.0
Galcanezumab-Gnlm51.31.3
Tirzepatide170.90.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.